Prosigna Breast Cancer Assay Now Approved for Reimbursement in Germany



*Veracyte has acquired the Prosigna test. Materials are in transition.

Prosigna is indicated for in vitro diagnostic use in postmenopausal women with hormone receptor-positive, node-negative (Stage I or II), or node-positive (Stage II) breast cancer to be treated with adjuvant endocrine therapy for assessment of risk of distant recurrence of disease.